Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
About Kronos Bio, Inc.
Kronos Bio, Inc. (Nasdaq: KRON) is a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription. Transcriptional dysregulation is a hallmark of many complex diseases, and Kronos Bio employs its proprietary discovery engine to decode transcription factor regulatory networks, identifying druggable cofactors that play critical roles in disease progression. By targeting these cofactors in a disease-specific context, the company aims to transform patient outcomes in areas of significant unmet medical need.
Proprietary Technology and Expertise
Kronos Bio's competitive edge lies in its proprietary discovery platform, which integrates high-throughput screening strategies and small molecule microarray (SMM) technology. This platform enables the company to identify and optimize small molecules that specifically target transcriptional drivers of disease. The focus on transcription factor regulatory networks allows Kronos Bio to address historically recalcitrant targets, opening new therapeutic possibilities in oncology and autoimmune diseases.
Pipeline and Therapeutic Focus
The company's pipeline includes multiple drug candidates at various stages of development:
- Istisociclib (KB-0742): A CDK9 inhibitor designed to address MYC deregulation in solid tumors, currently being evaluated in a Phase 1/2 clinical trial for platinum-resistant high-grade serous ovarian cancer.
- KB-9558: A p300 lysine acetyltransferase (KAT) inhibitor targeting IRF4 dependence in multiple myeloma and HPV-driven tumors, with preclinical data demonstrating potential tumor suppression through restoration of p53 and Rb pathways.
- KB-7898: Kronos Bio's first autoimmune development candidate, targeting Sjögren’s disease. This p300 KAT inhibitor modulates inflammatory signaling pathways and has shown preclinical efficacy in reducing inflammatory cytokines and antibody production.
By focusing on these disease-specific mechanisms, Kronos Bio aims to provide therapeutic solutions for patient populations with limited or no treatment options.
Market Position and Challenges
Operating within the highly competitive biopharmaceutical industry, Kronos Bio faces challenges such as the inherent risks of drug development, regulatory hurdles, and the need for substantial financial resources. However, its emphasis on transcriptional dysregulation as a therapeutic target sets it apart from competitors, offering a unique value proposition. The company's focus on oncology and autoimmune diseases—markets with high unmet medical needs—positions it as a key player in these segments.
Commitment to Innovation
Kronos Bio's mission is underpinned by a commitment to scientific excellence and innovation. By leveraging its advanced discovery engine and expertise in transcriptional biology, the company continues to push the boundaries of what is possible in drug discovery and development. Its efforts are directed toward creating first-in-class therapies that have the potential to significantly improve the lives of patients worldwide.
Kronos Bio, Inc. (Nasdaq: KRON) announced participation in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7 a.m. ET. The event will be webcast live and archived on the company's website for one month. Kronos Bio specializes in therapies aimed at cancer treatment, particularly through their investigational therapies like entospletinib for NPM1-mutated acute myeloid leukemia and KB-0742 for MYC-amplified solid tumors.
Kronos Bio, Inc. announced FDA clearance for its Investigational New Drug application for lanraplenib (LANRA) targeting acute myeloid leukemia (AML). The firm is set to launch a Phase 1/2 clinical trial in Q4 2021 and plans to initiate a Phase 3 trial for entospletinib (ENTO) in newly diagnosed NPM1-mutated AML patients. Financially, as of June 30, 2021, Kronos holds $419.3 million in cash, with a net loss of $29.1 million for Q2 2021. The company showcased its SYK inhibitor portfolio and plans to report key trial data in the coming months.
Kronos Bio has received FDA clearance for its IND application for lanraplenib (LANRA) to treat relapsed or refractory FLT3-mutated acute myeloid leukemia (AML). The first Phase 1/2 trial is set to begin in Q4 2021, with initial safety and efficacy data expected in late 2022. LANRA is positioned as a next-generation SYK inhibitor, with potential advantages in dosing compared to entospletinib (ENTO). The development strategy aims to leverage synergistic effects between LANRA and standard treatments to target genetic mutations in AML patients.
Kronos Bio, Inc. (Nasdaq: KRON) announced participation in two upcoming investor conferences. The management team will engage in fireside chats at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 a.m. ET, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 11:20 a.m. ET. These discussions will be webcast live on the company's website, with replays available for one month after each event. Kronos Bio focuses on developing cancer therapies, including SYK inhibitors and CDK9 inhibitors, to target specific mutations in cancer.
Kronos Bio (KRON) has revealed its development strategy for the SYK inhibitor portfolio, particularly lanraplenib (LANRA) and entospletinib (ENTO), targeting acute myeloid leukemia (AML). The company plans to begin two Phase 1/2 trials for LANRA and a Phase 3 trial for ENTO aimed at patients with NPM1 mutations. Furthermore, initial data from KB-0742, a CDK9 inhibitor for MYC-dependent solid tumors, is expected by Q4 2021. These advancements aim to address the needs of AML patients with specific genetic mutations that account for over two-thirds of cases.
Kronos Bio, Inc. (Nasdaq: KRON) reported significant developments during its recent quarterly update. As of March 31, 2021, the company had $440.6 million in cash and equivalents. Highlights include preclinical data for KB-0742 presented at AACR, indicating sustained tumor growth inhibition in multiple cancers. The FDA approved a positive End-of-Phase 2 meeting for SYK inhibitor entospletinib, paving the way for a Phase 3 trial in AML. R&D expenses were $17.6 million, while the net loss stood at $26.1 million or $0.48 per share.
Kronos Bio, Inc. (Nasdaq: KRON) will participate in a fireside chat at the Bank of America Securities 2021 Health Care Conference on May 13, 2021, at 1:15 p.m. ET. The event will be available via live webcast on the company's website, with a replay archived for one month. Kronos Bio focuses on developing therapies for cancer, with lead investigational therapy entospletinib aimed at treating NPM1-mutated acute myeloid leukemia (AML) and another candidate, KB-0742, targeting MYC-amplified solid tumors.
Kronos Bio, Inc. (Nasdaq: KRON) presented preclinical data at the AACR Annual Meeting 2021 for KB-0742, an innovative CDK9 inhibitor targeting MYC-amplified tumors. The findings indicated sustained tumor growth inhibition via intermittent dosing, with MYC genomic amplification identified as a key sensitivity factor. Initial clinical trial data for KB-0742 is expected in Q4 2021, with hopes to confirm these promising preclinical results translating to effective treatments in patients.
Kronos Bio, Inc. (Nasdaq: KRON) mourns the loss of board member and early investor John C. Martin, Ph.D., who passed away recently. Martin was recognized for his significant contributions to the life sciences and was instrumental in the development of major HIV treatments during his tenure at Gilead Sciences. His legacy includes philanthropic efforts through The John C. Martin Foundation, focusing on healthcare access in underserved populations. Kronos Bio is committed to continuing Martin's vision of transforming cancer therapies through innovative research.
Kronos Bio (Nasdaq: KRON) announced the appointment of Taiyin Yang, Ph.D., to its board of directors. Dr. Yang brings over 40 years of experience in pharma development, including significant roles at Gilead Sciences, where she led the creation of innovative treatments. Her expertise is expected to aid Kronos in advancing its clinical pipeline. Additionally, Jakob Loven will not seek re-election at the 2021 Annual Meeting. This change comes during a critical growth phase for Kronos, focused on cancer therapies like entospletinib and KB-0742.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
What does Kronos Bio specialize in?
What is Kronos Bio's proprietary discovery engine?
What are Kronos Bio's main therapeutic areas?
What are Kronos Bio's key drug candidates?
How does Kronos Bio differentiate itself from competitors?
What is Istisociclib (KB-0742)?
What is KB-9558 designed to treat?
What is KB-7898's therapeutic focus?
Where is Kronos Bio headquartered?
What challenges does Kronos Bio face?
